Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2022, 31(1):55-60

Transthyretin cardiac amyloidosis

Krajčík M
II. interná kliniky, Helios Vogtland-Klinikum Plauen, Röntgenstraße 2, 08529 Plauen, Nemecko

The incidence and prevalence of chronic heart failure is rising in all developed countries, with a prevalence of around 10% in people over 75 years of age. The most common cause of chronic heart failure is coronary heart disease, but in clinical practice in elderly patients other causes should be considered, one of which is senile transthyretin amyloidosis. The paper presents a patient in whom this diagnosis could have been overlooked due to associated chronic diseases.

Keywords: heart failure; amyloidosis; senile transthyretin amyloidosis

Published: January 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krajčík M. Transthyretin cardiac amyloidosis. Cardiology Letters. 2022;31(1):55-60.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200. doi:10.1093/eurheartj/ehw128 Go to original source...
    2. Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 2021;110:479-506. doi: 10.1007/s00392-020-01799-3. Go to original source...
    3. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation 2017;135:1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438. Go to original source...
    4. Kristen AV. Was am Herzen nagt und auf die Nerven geht. Der Internist 2018;11:1432-1289. doi:10.1007/s00108-018-0470-x. Go to original source...
    5. Rudolph T, Kurz MW, Farbu E. Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history. Clin Med Res. 2008;6:80-82. doi:10.3121/cmr.2008.794. Go to original source...
    6. Ruberg FL, Appelbaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009;103:544549. doi: 10.1016/j.amjcard.2008.09.105. Go to original source...
    7. Aljaroudi WA, Desai MY, Tang WH, et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014;21:271-283. doi: 10.1007/s12350-013-9800-5 Go to original source...
    8. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;22;2:e000098. doi: 10.1161/JAHA.113.000098. Go to original source...
    9. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;29;120:1203-1212. doi: 10.1161/CIRCULATIONAHA.108.843334. Go to original source...
    10. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20:117-124. doi: 10.1007/s10741-015-9480-0. Go to original source...
    11. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):12-26. doi: 10.3949/ccjm.84.s3.02 Go to original source...
    12. Kreusser MM, Volz MJ, Knop B, et al. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clin Res Cardiol. 2020;109:700-713. doi: 10.1007/s00392-01901559-y. Go to original source...
    13. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;14;35:2733-2779. doi: 10.1093/eurheartj/ehu284. Go to original source...
    14. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015; 20;132:1570-1579. doi: 10.1161/CIRCULATIONAHA.115.016567. Go to original source...
    15. Gillmore JD, MaurerMS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:24042412. doi: 10.1161/CIRCULATIONAHA.116.021612. Go to original source...
    16. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24:343-350. doi: 10.1016/j.carpath.2015.07.008. Go to original source...
    17. Maurer MS, Schwartz JH, Gundapaneni B, et al. ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;13:379:1007-1016. doi: 10.1056/NEJMoa1805689. Go to original source...

    Return to the content